Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase III trials

Journal of Clinical Oncology

Volumn 14, Issue 7, 1996, Pages 2000-2011

  Buzdar, A ^a   Jonat, W ^a   Howell, A ^a   Jones, S E ^a   Blomqvist, C ^a   Vogel, C L ^a   Eiermann, W ^a   Wolter, J M ^a   Azab, M ^a   Webster, A ^a   Plourde, P V ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; MEGESTROL ACETATE; TAMOXIFEN;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; FEMALE; FLUSHING; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PAIN; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING; WEIGHT GAIN;

EID: 8944237006     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.7.2000     Document Type: Article

References (29)

1. Mouridsen H, Palshof T, Patterson J, et al: Tamoxifen in advanced breast cancer. Cancer Treat Rev 5:131-141, 1978
2. Jordan VC: Tamoxifen for breast cancer prevention. Proc Soc Exp Biol Med 208:144-149, 1995
3. Early Breast Cancer Trialists' Research Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:1-15, 1992
4. Cruz JM, Muss HB, Brockschmidt JK, et al: Weight changes in women with metatstic breast cancer treated with megestrol acetate: A comparison of standard versus high-dose therapy. Semin Oncol 17:63-67, 1990
5. Henderson IC: Endocrine therapy in metastatic breast cancer, in Harris JR, Hellman S, Henderson IC, et al (eds): Breast Diseases (ed 2). Philadelphia, PA, Lippincott, 1991, pp 419-422
6. Stuart-Harris RC, Smith IE: Aminoglutethimide in the treatment of advanced breast cancer. Cancer Treat Rev 11:189-204, 1984
7. Coombes RC, Hughes SW, Dowsett M: 4-Hydroxyandrostenedione: A new treatment for postmenopausal women with advanced breast cancer. Eur J Cancer 28A:1941-1945, 1992
8. Goss PE, Gwynn KM: Current perspectives on aromatase inhibitors in breast cancer. J Clin Oncol 12:2460-2470, 1994
9. Plourde PV, Dyroff M, Dukes M: Arimidex: A potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res Treat 30:103-111, 1994
10. Hayward JL, Carbone PP, Heuson J-C, et al: Assessment of response to therapy in advanced breast cancer. Eur J Cancer 13:89-94, 1977
11. de Haes JCJM, van Knippenberg FCE, Neijt JP: Measuring psychological and physical distress in cancer patients: Structure and application of the Rotterdam Symptom Checklist. Br J Cancer 66:402-404, 1992
12. National Institutes of Health Consensus Development Conference Statement: Adjuvant chemotherapy for breast cancer. JAMA 254:3461-3463, 1985
13. Himel H, Liberati A, Gelber R, et al: Adjuvant chemotherapy for breast cancer pooled estimate based on published randomized control trials. JAMA 256:1148-1159, 1986
14. Yusuf S, Peto R, Lewis J, et al: Beta blockade during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis 27:335-371, 1985
15. Schacter LP, Rozencweig M, Canetta R, et al: Overview of hormonal therapy in advanced breast cancer. Semin Oncol 17:38-46, 1990 (suppl 9)
16. Gill PG, Gebski V, Snyder R, et al: Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer. Ann Oncol 4:741-744, 1993
17. Ingle JN, Ahmann DL, Green SJ, et al: Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer. Am J Clin Oncol 5:155-160, 1982
18. Morgan LR: Megestrol acetate v tamoxifen in advanced breast cancer in postmenopausal patients. Semin Oncol 12:43-47, 1985
19. Muss HB, Case LD, Capizzi RL, et al: High- versus standarddose megestrol acetate in women with advanced breast cancer: A phase III trial of the Piedmont Oncology Association. J Clin Oncol 8:1797-1805, 1990
20. Ingle JN, Green SJ, Ahmann DL, et al: Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer. J Clin Oncol 4:958-964, 1986
21. Mercer PM, Ebbs SR, Fraser SCA, et al: Trial of aminoglutethimide vs hydrocortisone as second-line hormone treatment of advanced breast cancer. Eur J Surg Oncol 19:254-258, 1993
22. Pronzato P, Rubagotti A, Amoroso D, et al: Second-line hormonotherapy for breast cancer. Usefulness of first-line continuation. Am J Clin Oncol 16:522-525, 1993
23. Dixon AR, Jackson L, Chan S, et al: A randomized trial of second-line hormone vs single agent chemotherapy in tamoxifen resistant breast cancer. Br J Cancer 66:402-404, 1992
24. Robertson JFR, Williams MR, Todd J, et al: Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy. Eur J Cancer Clin Oncol 23:469-475, 1989
25. Congdon J, Green S, O'Sullivan J, et al: Megestrol acetate (MA) and aminoglutethimide/hydrocortisone (Ag/HC) in sequence or combination as second-line endocrine therapy of oestrogen receptor positive metastatic breast cancer. Proc Am Soc Clin Oncol 10:93, 1991 (abstr 45)
26. Howell A, Mackintosh J, Jones M, et al: The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Cancer Clin Oncol 24:1567-1572, 1988
27. Loprinzi CL, Ellison NM, Schaid DJ, et al: Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 82:1127-1132, 1990
28. Von Roenn JH, Armstrong D, Kolter DP, et al: Megestrol acetae in patients with AIDS-related cachexia. Ann Intern Med 121:393-399, 1994
29. Patterson AHG, Hanson J, Prichard K, et al: Comparison of antiestrogen and progesterone therapy for initial treatment and consequences of their combination for second-line treatment of recurrent breast cancer. Semin Oncol 17:52-62, 1990